Aura Biosciences Inc. (AURA)
| Bid | 6.84 |
| Market Cap | 360.4M |
| Revenue (ttm) | 2.07M |
| Net Income (ttm) | -83.7M |
| EPS (ttm) | -1.73 |
| PE Ratio (ttm) | -4.17 |
| Forward PE | -3.87 |
| Analyst | Buy |
| Ask | 7.58 |
| Volume | 93,095 |
| Avg. Volume (20D) | 156,143 |
| Open | 7.53 |
| Previous Close | 7.49 |
| Day's Range | 7.20 - 7.40 |
| 52-Week Range | 6.63 - 12.38 |
| Beta | 0.29 |
About AURA
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was inc...
Analyst Forecast
According to 4 analyst ratings, the average rating for AURA stock is "Buy." The 12-month stock price forecast is $23, which is an increase of 218.78% from the latest price.
4 months ago · seekingalpha.com
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder ValueThe positive end of phase 2 study data was achieved using bel-sar for the treatment of patients with intermediate lesions and small choroidal melanoma. The global uveal melanoma treatment market is ex...